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Gestational impaired glucose tolerance does not increase
perinatal mortality in a developing country: cohort study
Shenaz Ramtoola, Philip Home, Hassen Damry, Anwar Husnoo, Stephen Ah›Kion
The high prevalence of diabetes and impaired glucose
tolerance in women of childbearing age in Mauritius
provides an opportunity to assess prospectively the
risks of adverse outcome in pregnancy of these condi›
tions, whether the conditions are known to be present
at conception or diagnosed during pregnancy.1 The
findings are likely to have consequences for healthcare
planning in developing countries.
Participants, methods, and results
The study hospital (catchment population 250 000;
4500 deliveries a year) accounts for 22% of deliveries of
babies in Mauritius, hospital deliveries being 80% of all
deliveries on the island.1 Cases were registered in 1993›6
at a joint obstetric and medical service for diabetes, and
were also found by monitoring admissions to the obstet›
ric wards, and by monitoring all requests for obstetric
oral glucose tolerance tests. Data were collected from the
mother and from hospital and national records.
Diabetes and impaired glucose tolerance were diag›
nosed using the 1985 WHO criteria.2 Outcomes were
assessed as miscarriage ( < 28 weeks), stillbirth, live birth,
or neonatal death ( < 1 week). Neonatal data were
obtained from neonatal records, and background infor›
mation was obtained from national statistics and
routinely collected hospital obstetric data. Standard sta›
tistical tests were used for analysis of categorical and
continuous data.
A total of 294 glucose intolerant pregnancies were
registered in 270 women with diabetes or impaired
glucose tolerance (mean age 31; SD 6 years). Of these,
110 cases were of pregestational onset and the remain›
der were diagnosed during pregnancy (86 diabetes, 98
impaired glucose tolerance); nine were lost to follow
up and 18 miscarried.
Outcome in the 267 pregnancies resulting in live
birth or stillbirth is shown in the table. Perinatal
Outcome of pregnancy in Mauritius, 1993›6, according to diagnostic category of glucose intolerance. Values are number (percentage)
unless otherwise indicated
Pregestational diabetes Gestational diabetes
Gestational impaired
glucose tolerance
Background
population
Perinatal mortality per 1000 births 124 116 22 26
Relative risk (95% CI) 4.7 (2.7 to 8.2) 4.4 (2.5 to 7.9) 0.8 (0.2 to 3.3)
Stillbirth per 1000 births 67 81 11 14
Relative risk (95% CI) 4.8 (2.2 to 10.3) 5.7 (2.8 to 11.7) 0.8 (0.1 to 5.4)
Early neonatal mortality per 1000 live births 60 38 11 12
Relative risk (95% CI) 4.9 (2.1 to 11.6) 3.1 (1.0 to 9.4) 0.9 (0.1 to 6.3)
Mean (SD) birthweight (g) 3059 (641) 3293 (714) 3083 (603) 2953 (567)
P value (v background population) NS 0.001 0.05
Macrosomia (>4000 g) 7 (8) 14 (16) 6 (7) 147 (3)
Relative risk (95% CI) 2.4 (1.2 to 4.9) 4.9 (3.0 to 8.1) 2.0 (0.9 to 4.3)
P value (v background population) 0.05 0.001 NS
Mean (SD) gestational age (weeks) 37.0 (2.4) 37.7 (2.3) 38.5 (1.8) NA
P value (v pregestational diabetes/gestational diabetes) NS 0.05 0.001/0.05
Prematurity (<37 weeks) 33 (37) 19 (22) 10 (11) NA
P value (v pregestational diabetes/gestational diabetes) NS 0.05 0.001/0.05
Caesarean section 51 (58) 49 (57) 40 (43) 16
P value (v background population) 0.001 0.001 0.001
Hypoglycaemia in infant (<1.7 mmol/l) 17 (21) 11 (14) 4 (4) NA
P value (v gestational impaired glucose tolerance) 0.001 0.05 NS
Hyperbilirubinaemia in infant 28 (35) 30 (39) 19 (21) NA
P value (v gestational impaired glucose tolerance) 0.05 0.05 NS
NA=data not available.NS=not significant.
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mortality was 124/1000 for women with pregesta›
tional diabetes and 116/1000 for women with
gestational diabetes, giving relative risks well above the
rate in the background population (26/1000). There
was no excess perinatal mortality in women with
gestational impaired glucose tolerance (22/1000). The
excess perinatal mortality in women with pregesta›
tional diabetes comprised a similar excess of stillbirths
and early neonatal mortality; in gestational diabetes it
was related particularly to an excess of stillbirths
(81/1000). All but one of the cases of perinatal
mortality in gestational diabetes occurred in 43 women
who had fasting hyperglycaemia >7.8 mmol/l at
presentation.
Mean birth weight was significantly higher in
babies born to women with gestational diabetes and
impaired glucose tolerance than in the background
population but not in babies born to women with
pregestational diabetes (table). The incidence of
macrosomia was highest in the gestational diabetes
group and was also significantly increased in the
pregestational diabetes group. It was not significantly
increased in the group with gestational impaired
glucose tolerance, despite this group having the
highest gestational age at delivery. Four infants of
mothers with pregestational or gestational diabetes
weighed>4500 g (2%; relative risk 9.2 (3.0 to 29.0)) but
none weighed >4500 g in the group with gestational
impaired glucose tolerance. Rates of caesarean section
were significantly above background in all the glucose
intolerant groups (table). Both hypoglycaemia and
hyperbilirubinaemia were significantly more common
in infants of women with pregestational and
gestational diabetes than in those of women with
gestational impaired glucose tolerance (table).
Comment
In Mauritius women diagnosed as frankly diabetic dur›
ing pregnancy carry the same risks as women with
pregestational diabetes, but pregnancies with
gestational impaired glucose tolerance have an
outcome identical to that of the background popula›
tion across several measures. This is consistent with
reports from Belfast and Bangkok.3 4 The 1999 WHO
Consultation reiterated that the term “gestational
diabetes” should encompass both gestational impaired
glucose tolerance and diabetes, and that women with
impaired glucose tolerance should be managed as
women with frank diabetes.5 Worldwide, most cases
found on screening in pregnancy are of impaired glu›
cose tolerance rather than diabetes.3 4 Our data do not
support using limited resources in developing coun›
tries to identify women with impaired glucose
tolerance and to manage them in line with WHO
recommendations.
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A memorable patient
The man who had 42 psychiatrists (and rising)
Moving on to my next post on a psychiatric training rotation
some years ago I met Mr L in my first outpatient clinic. He had a
huge file and had been in follow up for 20 years. As he came
through the door he announced, “That drug therapy the last
doctor prescribed isn’t working, you know doctor.” Then he sat
down and, far from being jaded by the repeated re›telling,
launched into a sparkling resumØ of his chronic symptoms and
worries. My first reaction (a little naive) was to marvel at the
renewability of long›standing neurotic illness—the way it could be
poured out at any time as if freshly minted.
However, my second reflection was that the institutionally
minded field of psychiatry was as much the author of the shape
and substance of Mr L’s psychiatric career as he was. Every six
months for 20 years a new registrar on rotation had listened to
his ailments and tinkered with his medication, but little more. I,
registrar number 41, resolved to try to shift the paradigm away
from psychiatric patienthood and its dependence on doctor
legitimated inability to cope towards recovery of functioning and
autonomy as an ordinary citizen. Before long he seemed to
respond to this new music, and he began to mention the pills less
(I wanted to phase these out) and to talk the language of social
rehabilitation. Encouraged by this, when the time came for me to
move on to my next post I suggested that he continue with me for
sessions of reducing frequency (aiming for discharge). He agreed.
He saw me twice after I moved, but then he dropped out. I don’t
doubt that he returned to the old set up and was taken back.
Mr L’s opening salvo may be seen as putting the new doctor on
his mettle. With hindsight, what might be discerned from our
subsequent interactions was an impulse to keep the doctor
interested and even a modest optimism that the new doctor
might achieve something where a lengthening list of predecessors
had failed. He picked up what I wanted to hear and for a while he
gave it to me (for a while he may have also have believed some of
it himself). But it is hard to give up a way of being embedded over
many years, and in the end he decided that the old music, and old
dance routines and partners, were better. And thus I imagine that
as he came through the door to see registrar number 42 for the
first time he announced, “That anti›sick role therapy the last
doctor prescribed isn’t working, you know doctor.”
Derek Summerfield honorary senior lecturer, Department of
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